CTC’s CIR approval opens up further opportunities with French biotech and pharmaceutical companies planning clinical studies in Europe.


Under France’s Crédit d’Impôt Recherche (CIR) scheme, eligible R&D expenditure with CTC may qualify for a research tax credit of up to 30%, helping reduce the cost supporting early phase programs.

 We combine full-service CRO capabilities with in-house clinical sites in Sweden, supporting first-in-human, Phase I and Phase II studies.

Contact our team to discuss how we can support your next study.